An alternative method for screening EGFR mutation using RFLP in non-small cell lung cancer patients

Journal of Thoracic Oncology

Volumn 3, Issue 10, 2008, Pages 1096-1103

  Kawada, Ichiro ^a   Soejima, Kenzo ^b   Watanabe, Hideo ^b   Nakachi, Ichiro ^b   Yasuda, Hiroyuki ^b   Naoki, Katsuhiko ^c   Kawamura, Masafumi ^b   Eguchi, Keisuke ^b   Kobayashi, Koichi ^b   Ishizaka, Akitoshi ^b  

^a Hino Municipal Hospital   (Japan)

^b KEIO UNIVERSITY   (Japan)

^c YOKOHAMA MUNICIPAL CITIZEN'S HOSPITAL   (Japan)

Author keywords

EGFR mutation; Non small cell lung cancer; RFLP

Indexed keywords

COMPLEMENTARY DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; DNA; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER PATIENT; EXON; FEMALE; GENE MUTATION; GENE SEQUENCE; GENETIC SCREENING; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCREENING TEST; TREATMENT RESPONSE; ADENOCARCINOMA; CANCER STAGING; DRUG ANTAGONISM; GENETICS; LARGE CELL CARCINOMA; LUNG TUMOR; METHODOLOGY; MIDDLE AGED; MUTATION; SQUAMOUS CELL CARCINOMA;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; DNA, NEOPLASM; FEMALE; GENETIC SCREENING; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR MARKERS, BIOLOGICAL;

EID: 58949091382     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e318186fadd     Document Type: Article

References (25)

1. Jemal A, Murray T, Ward E, et al. American Cancer Society Cancer statistics, 2005. Cancer J Clin 2005;55:10-30.
2. Tanovic A, Alfaro V. Gefitinib. Current status in the treatment of non-small cell lung cancer. Drugs Today (Barc) 2004;40:809-827.
3. Ross JS, Schenkein DP, Pietrusko R, et al. Targeted therapies for cancer 2004. Am J Clin Pathol 2004;122:598-609.
4. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-2139.
5. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304: 1497-1500.
6. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and elrotinib. Proc Natl Acad Sci USA 2004;101:13306-13311.
7. Sordella R, Bell DW, Haber DA, et al. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 2004;305:1163-1167.
8. Han SW, Kim TY, Hwang PG, et al. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small cell lung cancer patients treated with gefitinib. J Clin Oncol 2005;23:2493-2501.
9. Mitsudomi T, Kosaka T, Endoh H, et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small cell lung cancer with postoperative recurrence. J Clin Oncol 2005;23:2513-2520.
10. Takano T, Ohe Y, Sakamoto H, et al. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small cell lung cancer. J Clin Oncol 2005;23:6829-6837.
11. Kobayshi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non-small cell lung cancer to gefitinib. N Engl J Med 2005; 352:786-792.
12. Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005;2:e73.
13. Tomizawa Y, Iijima H, Sunaga N, et al. Clinicopathologic significance of the mutations of the epidermal growth factor receptor gene in patients with non-small cell lung cancer. Clin Cancer Res 2005;11:6816-6822.
14. Kuo CW, Chen YM, Chao JY, et al. Non-small cell lung cancer in very young and very old patients. Chest 2000;117:354-357.
15. Cappuzzo F, Varella-Garcia M, Shigematsu H, et al. Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small cell lung cancer patients. J Clin Oncol 2005;23:5007-5018.
16. Jackman DM, Yeap BY, Sequist LV, et al. Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res 2006;12:3908-3914.
17. Bosari S, Marchetti A, Buttitta F, et al. Detection of p53 mutations by single-strand conformation polymorphisms (SSCP) gel electrophoresis: a comparative study of radioactive and nonradioactive silver-stained SSCP analysis. Diagn Mol Pathol 1995;4:249-255.
18. Wookey A, Ellison G, Donald E. Comparison of methods for the detection of mutations in the epithelial growth factor receptor gene. In 96th Ann Meeting Am Assoc Cancer Res 2005;46:1250, abstract 5287.
19. Kimura H, Kasahara K, Kawaishi M, et al. Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small cell lung cancer. Clin Cancer Res 2006;12:3915-3921.
20. Sasaki H, Endo K, Konishi A, et al. EGFR mutation status in Japanese lung cancer patients: genotyping analysis using LightCycler. Clin Cancer Res 2005;11:2924-2929.
21. Marchetti A, Martella C, Felicioni L, et al. EGFR mutations in non-small cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol 2005;23:857- 865.
22. Nagai Y, Miyazawa H, Huqun, et al. Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp. Cancer Res 2005;65:7276-7282.
23. Asano H, Toyooka S, Tokumo M, et al. Detection of EGFR gene mutation in lung cancer by mutant-enriched polymerase chain reaction assay. Clin Cancer Res 2006;12:43-48.
24. Chan SK, Gullick WJ, Hill ME. Mutations of the epidermal growth factor receptor in non-small cell lung cancer-search and destroy. Eur J Cancer 2006;42:17-23.
25. Real FX, Rettig WJ, Chesa PG, et al. Expression of epidermal growth factor receptor in human cultured cells and tissues: relationship to cell lineage and stage of differentiation. Cancer Res 1986;46:4726-4731.